- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Carpenter syndrome.
Displaying page 1 of 1.
EudraCT Number: 2020-000439-32 | Sponsor Protocol Number: NW-3509/015/II/2019 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||
Full Title: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophre... | |||||||||||||
Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000986-37 | Sponsor Protocol Number: F1D-MC-HGKB | Start Date*: 2004-11-26 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder | ||
Medical condition: Schizophrenia or Schizoaffective Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001387-20 | Sponsor Protocol Number: ELA026-CP002 | Start Date*: 2021-10-11 | ||||||||||||||||
Sponsor Name:Electra Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymph... | ||||||||||||||||||
Medical condition: sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients r... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000437-41 | Sponsor Protocol Number: NW-3509/014/II/2019 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||
Full Title: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients... | |||||||||||||
Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006062-36 | Sponsor Protocol Number: NW-3509/008A/II/2020 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Newron Pharmaceuticals S.p.A. | |||||||||||||
Full Title: A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M... | |||||||||||||
Medical condition: Chronic schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) HU (Completed) PL (Completed) EE (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018563-41 | Sponsor Protocol Number: SL0009 | Start Date*: 2011-05-25 | |||||||||||
Sponsor Name:UCB Inc. | |||||||||||||
Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosu... | |||||||||||||
Medical condition: Systemic Lupus Erythmatosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) CZ (Completed) GB (Completed) BG (Completed) LT (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018565-26 | Sponsor Protocol Number: SL0010 | Start Date*: 2011-01-16 | |||||||||||
Sponsor Name:UCB Inc. | |||||||||||||
Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosu... | |||||||||||||
Medical condition: Systemic Lupus Erythmatosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) DE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001514-15 | Sponsor Protocol Number: EARLY_KUM_PSY | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Bezirkskliniken Schwaben | |||||||||||||
Full Title: Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002093-34 | Sponsor Protocol Number: NW-3509/020/III/2021 | Start Date*: 2021-11-12 | |||||||||||||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||||||||||||
Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre... | |||||||||||||||||||||||
Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004157-99 | Sponsor Protocol Number: F1D-MC-HGLQ | Start Date*: 2006-02-16 |
Sponsor Name:Lilly S.A. | ||
Full Title: Estudio aleatorizado, abierto en el que se comparan los efectos del pamoato de olanzapina depot con los de olanzapina oral en los resultados del tratamiento en pacientes ambulatorios con esquizofrenia | ||
Medical condition: Esquizofrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) PT (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020859-30 | Sponsor Protocol Number: SL0012 | Start Date*: 2011-05-25 | |||||||||||
Sponsor Name:UCB Inc. | |||||||||||||
Full Title: A phase 3, multicenter, open-label, extension study to asssess the safety and tolerability of Epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4) | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) GB (Prematurely Ended) HU (Completed) BG (Prematurely Ended) LT (Prematurely Ended) IT (Completed) EE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
